RIFM Adopts BlueScreen HC™ for Early Genetic Toxicology Screening of Fragrance Materials
News Jun 19, 2013
RIFM is a non-profit research institute whose purpose is to gather and analyse scientific data, engage in testing and evaluation, distribute information, cooperate with official agencies and to encourage uniform safety standards related to the use of fragrance ingredients. To meet these goals, RIFM takes advantage of recent innovations in risk assessment methodology. The use of BlueScreen™ HC provides accurate, sensitive results that are efficiently integrated into RIFM’s testing cascade and enable more efficient fragrance material evaluation.
BlueScreen™ HC is a highly specific, sensitive human cell based assay used to screen chemicals for their potential to cause damage to DNA: a property known as genotoxicity. Based on technology already used in the pharmaceutical industry, BlueScreen HC is used to provide a rapid assessment of potential hazard across diverse chemical collections in the assessment of new chemicals that are candidates for product development.
The assay evaluates the up-regulation of a key gene’s, GADD45a, response to a chemical that causes damage to, or interferes with, DNA. It measures the luminescence generated from the enzyme Gaussia Luciferase from the marine crustacean Gaussia princeps.
The gene is incorporated into the human TK6 cells used in the assay and linked to GADD45a production.
RIFM and the originators of BlueScreen HC, Gentronix Limited are working closely on the assessment of fragrance materials for use in a wide range of consumer products.
“We found BlueScreen™ HC to be a very useful tool in our fragrance material evaluation process” said RIFM President, Dr. David Wilcox.
Gentronix Commercial Director, Dr. Steve Beasley said: “We have been impressed with the scientific rigor that RIFM brings to the safety evaluation of fragrance materials and their assessment of new technologies such as BlueScreen HC. We look forward to continuing this important collaboration.”
Immune checkpoint inhibitors (ICIs) are an emerging type of cancer immunotherapy that uses the immune system to attack cancer cells. However, in some patients they cause the immune system to attack healthy cells – when pancreatic beta cells are attacked, this can lead to type 1 diabetes.READ MORE